Norges Bank’s VistaGen Therapeutics VTGN Stock Holding History

Norges Bank’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,960	Closed	-$1.64M	–	2176
2022 Q1	$1.64M	Buy	+43,960	New	+$1.92M	﹤0.01%	2004

Other funds holding VTGN

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NIP

Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's VTGN Position: Q2 2022 in Review

Norges Bank sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 43,960 shares — an estimated $1.64M sold.

Norges Bank first reported a position in VTGN in Q1 2022 and held it in 1 quarter. The position peaked at $1.64M in Q1 2022. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

Norges Bank reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 43,960 VistaGen Therapeutics shares in Q2 2022, an estimated $1.64M.
Norges Bank first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 1 quarter.
Norges Bank's VistaGen Therapeutics position peaked at $1.64M in Q1 2022.
112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.